Clinical trial
Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6…
NCT00317161 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00317161 |
|---|---|
| Title | Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose. |
| Official title | Study to Show Lot-to-lot Consistency of Hib-MenAC Mixed With Tritanrix™-HBV, Its Non-inferiority to Tritanrix™-HBV/Hiberix™ With or Without Meningitec™, and MenA Response in 2, 4, 6 Month Infants With Hepatitis B Birth Dose |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diphtheria, Hepatitis B, Haemophilus Influenzae Type b, Whole Cell Pertussis, Tetanus |
| Intervention type | Biological |
| Interventions | DTPw-HBV/Hib-MenAC conjugate vaccine |
| Enrollment | 1,000 |
| Start date | Aug 1, 2004 |
| Primary completion | Apr 1, 2005 |
| Completion | Apr 1, 2005 |
| First posted | Apr 24, 2006 |
| Last update posted | Sep 20, 2016 |
| Countries | Thailand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: